Critical Insights From Tandem Diabetes Care Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Tandem Diabetes Care (NASDAQ:TNDM) has received a range of analyst ratings over the past quarter, with a majority being bullish. Analysts have also raised their 12-month price targets, indicating positive sentiment. Despite this, the company faces challenges in profitability and financial performance compared to industry averages.
August 08, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tandem Diabetes Care has received predominantly bullish ratings from analysts, with several raising their price targets. The average 12-month price target is now $57.18, up from $48.67. However, the company faces challenges in profitability and financial performance compared to industry averages.
The majority of analysts have given bullish ratings and raised their price targets, indicating positive sentiment. However, the company's financial performance metrics such as net margin, ROE, and ROA lag behind industry averages, which could temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100